The benchmark equity indices snapped their two-session winning streak on Monday. The NSE Nifty 50 ended 19.65 points or 0.08% ...

Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...

Integrated Industries has raised ₹101.5 crore through 4.06 crore convertible warrants at ₹25 each, aimed at expanding ...

When we zoom out even further on the time horizon, Build-A-Bear really pulls away. While the S&P 500 has produced a healthy ...

RAD 101 is Radiopharm’s novel small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid ...

Dec 15 (Reuters) - Australia’s Fortescue said on Monday it will buy the remaining 64% of Alta Copper in a deal implying a total equity value of C$139 million ($101 million) for the Toronto-listed ...

If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain ...

While the Federal Reserve cut interest rates in the US a couple of days back, in Australia, the trend appears to be moving in ...

Atlantaa said that it has entered into a development agreement with Highway Milton Co-operative Housing Society for the redevelopment of a residential project in Borivali, Mumbai. The project is ...

Analyst price targets on Nvidia (NASDAQ:NVDA) stock were initially all over the place. The rally has continued for over 3 ...

In a boost for its phase III Indonesian diabetic foot infection trial, Recce becomes eligible for up to $85 million of ...